Journal
CANCER TREATMENT REVIEWS
Volume 40, Issue 4, Pages 523-532Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2013.11.006
Keywords
Osteosarcoma; Systemic treatment; Outcome; Prognostic factors; Metastatic disease; Mifamurtide; Interferon alpha
Categories
Funding
- Takeda GmbH
Ask authors/readers for more resources
Long-term outcome for patients with high-grade osteosarcoma has improved with the addition of systemic chemotherapy, but subsequent progress has been less marked. Modern, multiagent, dose-intensive chemotherapy in conjunction with surgery achieves a 5-year event-free survival of 60-70% in extremity localized, non-metastatic disease. A major, as yet unsolved, problem is the poor prognosis for metastatic relapse or recurrence, and for patients with axial disease. This article reviews the current state of the art of systemic osteosarcoma therapy by focusing on the experiences of cooperative osteosarcoma groups. Also, we shed light on questions and challenges posed by the aggressiveness of the tumor, and we consider potential future directions that may be critical to progress in the prognosis of high-grade osteosarcoma. (C) 2014 Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available